nach oben

Diabetologia

Erschienen in:

03.11.2018 | Commentary

Capturing residual beta cell function in type 1 diabetes

verfasst von: Flemming Pociot

Erschienen in: Diabetologia | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Since the 1970s, C-peptide has been used as a surrogate marker for monitoring the progression of type 1 and type 2 diabetes and to determine the effects of interventions designed to preserve or improve residual beta cell function. C-peptide measurement is a well-established surrogate of residual beta cell activity and of clinical significance as it is associated with HbA_1c, risk for microvascular complications and the incidence of hyperglycaemia in longitudinal studies. Measurement of C-peptide after a mixed meal tolerance test is considered the gold standard of measuring beta cell function in type 1 diabetes, but the method is laborious and inconvenient. In this issue of Diabetologia, Wentworth et al (https://doi.org/10.1007/s00125-018-4722-z) report an algorithm for estimating C-peptide (CP_EST) based on six routine clinical measures. These do not include stimulated C-peptide measurement and outperform other prevailing algorithms for estimating residual beta cell function. Going forward it is very likely that this new algorithm will serve as a simple measure of beta cell function in routine practice and as a more acceptable primary outcome measure in future trials of disease-modifying therapies.

Jones AG, Hattersley AT (2013) The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30(7):803–817. https://doi.org/10.1111/dme.12159 CrossRefPubMedPubMedCentral

Sacks DB, Arnold M, Bakris GL et al (2011) Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 34(6):1419–1423. https://doi.org/10.2337/dc11-9997 CrossRefPubMedPubMedCentral

Handelsman Y, Bloomgarden ZT, Grunberger G et al (2015) American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract 21(Suppl 1):1–87. https://doi.org/10.4158/EP15672.GLSUPPL CrossRefPubMedPubMedCentral

Lachin JM, McGee P, Palmer JP, Group DER (2014) Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 63(2):739–748. https://doi.org/10.2337/db13-0881 CrossRefPubMedPubMedCentral

Madsbad S, Alberti KG, Binder C et al (1979) Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. BMJ 2(6200):1257–1259. https://doi.org/10.1136/bmj.2.6200.1257 CrossRefPubMed

Steele C, Hagopian WA, Gitelman S et al (2004) Insulin secretion in type 1 diabetes. Diabetes 53(2):426–433. https://doi.org/10.2337/diabetes.53.2.426 CrossRefPubMed

Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26(3):832–836. https://doi.org/10.2337/diacare.26.3.832 CrossRefPubMed

Greenbaum CJ, Harrison LC, Immunology of Diabetes Society (2003) Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 52(5):1059–1065. https://doi.org/10.2337/diabetes.52.5.1059 CrossRefPubMed

Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2012) Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with type 2 diabetes. Diabet Med 29(1):90–93. https://doi.org/10.1111/j.1464-5491.2011.03428.x CrossRefPubMed

10.

Gjessing HJ, Matzen LE, Faber OK, Froland A (1989) Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 32(5):305–311. https://doi.org/10.1007/BF00265547 CrossRefPubMed

11.

Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53(1):250–264. https://doi.org/10.2337/diabetes.53.1.250 CrossRefPubMed

12.

Little RR, Wielgosz RI, Josephs R et al (2017) Implementing a reference measurement system for C-peptide: successes and lessons learned. Clin Chem 63(9):1447–1456. https://doi.org/10.1373/clinchem.2016.269274 CrossRefPubMedPubMedCentral

13.

Leighton E, Sainsbury CA, Jones GC (2017) A practical review of C-peptide testing in diabetes. Diabetes Ther 8(3):475–487. https://doi.org/10.1007/s13300-017-0265-4 CrossRefPubMedPubMedCentral

14.

Willemsen RH, Burling K, Barker P et al (2018) Frequent monitoring of C-peptide levels in newly diagnosed type 1 subjects using dried blood spots collected at home. J Clin Endocrinol Metab 103(9):3350–3358. https://doi.org/10.1210/jc.2018-00500 CrossRefPubMedPubMedCentral

15.

Ludvigsson J (1983) Methodological aspects on C-peptide measurements. Acta Medica Scand Suppl 671:53–59

16.

Mirel RD, Ginsberg-Fellner F, Horwitz DL, Rayfield EJ (1980) C-peptide reserve in insulin-dependent diabetes. Comparative responses to glucose, glucagon and tolbutamide. Diabetologia 19(3):183–188. https://doi.org/10.1007/BF00275266 CrossRefPubMed

17.

Greenbaum C, Seidel K, Pihoker C (2004) The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes. Diabetes Care 27(5):1202–1204. https://doi.org/10.2337/diacare.27.5.1202 CrossRefPubMed

18.

Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352(25):2598–2608. https://doi.org/10.1056/NEJMoa043980 CrossRefPubMed

19.

Berger B, Stenstrom G, Sundkvist G (2000) Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 60(8):687–693CrossRefPubMed

20.

Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31(10):1966–1971. https://doi.org/10.2337/dc07-2451 CrossRefPubMedPubMedCentral

21.

Faber OK, Binder C (1977) C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 26(7):605–610. https://doi.org/10.2337/diab.26.7.605 CrossRefPubMed

22.

Panero F, Novelli G, Zucco C et al (2009) Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 32(2):301–305. https://doi.org/10.2337/dc08-1241 CrossRefPubMedPubMedCentral

23.

The DCCT Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 128:517–523CrossRef

24.

Greenbaum CJ, Anderson AM, Dolan LM et al (2009) Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 32(10):1839–1844. https://doi.org/10.2337/dc08-2326 CrossRefPubMedPubMedCentral

25.

Sorensen JS, Vaziri-Sani F, Maziarz M et al (2012) Islet autoantibodies and residual beta cell function in type 1 diabetes children followed for 3-6 years. Diabetes Res Clin Pract 96(2):204–210. https://doi.org/10.1016/j.diabres.2011.12.013 CrossRefPubMed

26.

Davis AK, DuBose SN, Haller MJ et al (2015) Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 38(3):476–481. https://doi.org/10.2337/dc14-1952 CrossRefPubMed

27.

Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP, Group DPTS (2014) Distribution of C-peptide and its determinants in North American children at risk for type 1 diabetes. Diabetes Care 37(7):1959–1965. https://doi.org/10.2337/dc13-2603 CrossRefPubMedPubMedCentral

28.

Mortensen HB, Hougaard P, Swift P et al (2009) New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 32(8):1384–1390. https://doi.org/10.2337/dc08-1987 CrossRefPubMedPubMedCentral

29.

Andersen ML, Rasmussen MA, Pörksen S et al (2013) Complex multi-block analysis identifies new immunologic and genetic disease progression patterns associated with the residual β-cell function 1 year after diagnosis of type 1 diabetes. PLoS One 8(6):e64632. https://doi.org/10.1371/journal.pone.0064632 CrossRefPubMedPubMedCentral

30.

Max Andersen ML, Hougaard P, Pörksen S et al (2014) Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes. Pediatr Diabetes 15(7):469–476. https://doi.org/10.1111/pedi.12208 CrossRefPubMed

31.

Nagl K, Hermann JM, Plamper M et al (2017) Factors contributing to partial remission in type 1 diabetes: analysis based on the insulin dose-adjusted HbA1c in 3657 children and adolescents from Germany and Austria. Pediatr Diabetes 18(6):428–434. https://doi.org/10.1111/pedi.12413 CrossRefPubMed

32.

Nielens N, Polle O, Robert A, Lysy PA (2018) Integration of routine parameters of glycemic variability in a simple screening method for partial remission in children with type 1 diabetes. J Diabetes Res 2018:5936360CrossRefPubMedPubMedCentral

33.

Redondo MJ, Libman I, Cheng P et al (2018) Racial/ethnic minority youth with recent-onset type 1 diabetes have poor prognostic factors. Diabetes Care 41(5):1017–1024. https://doi.org/10.2337/dc17-2335 CrossRefPubMed

34.

Lundberg RL, Marino KR, Jasrotia A et al (2017) Partial clinical remission in type 1 diabetes: a comparison of the accuracy of total daily dose of insulin of <0.3 units/kg/day to the gold standard insulin-dose adjusted hemoglobin A_1c of ≤9 for the detection of partial clinical remission. J Pediatr Endocrinol Metab 30(8):823–830. https://doi.org/10.1515/jpem-2017-0019 CrossRefPubMed

35.

Boyle KD, Keyes-Elstein L, Ehlers MR et al (2016) Two- and four-hour tests differ in capture of c-peptide responses to a mixed meal in type 1 diabetes. Diabetes Care 39(6):e76–e78. https://doi.org/10.2337/dc15-2077 CrossRefPubMedPubMedCentral

36.

Wentworth JM, Bediaga NG, Giles LC et al (2018) Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables. Diabetologia. https://doi.org/10.1007/s00125-018-4722-z

37.

Barker A, Lauria A, Schloot N et al (2014) Age-dependent decline of beta-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab 16(3):262–267. https://doi.org/10.1111/dom.12216 CrossRefPubMed

38.

Ludvigsson J, Carlsson A, Deli A et al (2013) Decline of C-peptide during the first year after diagnosis of type 1 diabetes in children and adolescents. Diabetes Res Clin Pract 100(2):203–209. https://doi.org/10.1016/j.diabres.2013.03.003 CrossRefPubMed

39.

Kuhtreiber WM, Washer SL, Hsu E et al (2015) Low levels of C-peptide have clinical significance for established type 1 diabetes. Diabet Med 32(10):1346–1353. https://doi.org/10.1111/dme.12850 CrossRefPubMedPubMedCentral

40.

Wang L, Lovejoy NF, Faustman DL (2012) Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 35(3):465–470. https://doi.org/10.2337/dc11-1236 CrossRefPubMedPubMedCentral

Titel: Capturing residual beta cell function in type 1 diabetes
verfasst von: Flemming Pociot
Publikationsdatum: 03.11.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 1/2019
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-018-4768-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Capturing residual beta cell function in type 1 diabetes

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Clinical outcomes of an integrated primary–secondary model of care for individuals with complex type 2 diabetes: a non-inferiority randomised controlled trial

The deubiquitinating enzyme USP19 modulates adipogenesis and potentiates high-fat-diet-induced obesity and glucose intolerance in mice

Effect of l-arginine on energy metabolism, skeletal muscle and brown adipose tissue in South Asian and Europid prediabetic men: a randomised double-blinded crossover study

Global trends in diabetes complications: a review of current evidence

Effect of screening for type 1 diabetes on early metabolic control: the DiPiS study

Basal fatty acid oxidation increases after recurrent low glucose in human primary astrocytes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin